VJVirtual | ADCs for lung cancer

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, talks on ongoing clinical trials in non-small cell lung cancer (NSCLC) comparing antibody-drug conjugates (ADCs) targeting TROP2 versus docetaxel as well trials evaluating ADCs in the front-line, holding the potential to replace chemotherapy in this setting for certain subgroups of patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.